Treatment patterns and outcomes in elderly patients with ovarian cancer: a real-world data analysis
Frontiers in Oncology · 18.11.2026 · 16
DOI: 10.3389/fonc.2026.1977324 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 18.11.2026. Verfasst von Anna Norbeck und 3 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lunds Universitet.
Abstract (Originalsprache)
Background
Advanced ovarian cancer affects predominantly older patients, who often present with increased frailty and comorbidities. Older patients with ovarian cancer are underrepresented in clinical trials, and real-world data regarding treatment tolerance and survival in the oldest age groups remain limited. We evaluated surgical approach, chemotherapy completion, and overall survival in patients aged 70 years and older, stratified into 70–79 and ≥80 years, and compared outcomes with those of patients younger than 70 years. Particular attention was given to patients aged ≥80 years, for whom data are especially scarce.
Methods
A retrospective cohort study included 485 patients with advanced ovarian cancer referred to Skåne University Hospital, Lund, Sweden, between January 2018 and December 2023. Patients were stratified into three age groups: <70 years, 70–79 years, and ≥80 years. Baseline characteristics were compared using descriptive statistics. Survival probabilities at 12, 24 and 36 months were estimated using Kaplan–Meier analysis, and Restricted Mean Survival Time was calculated for the same intervals.
Results
Radical surgery was performed in 72.6% of patients <70 years, 61.4% of those aged 70–79 years, and 43.5% of patients ≥80 years (p=0.026). Completion of standard six chemotherapy cycles decreased with age: 95.0% in patients <70 years, 89.7% in the 70–79 group, and 73.9% among those ≥80 years (p=0.001). Patients <70 years undergoing primary debulking surgery had the highest 36‑month survival (74.0%). In patients ≥80 years, corresponding 36‑month survival was 42.5%.
Conclusion
Older patients with advanced ovarian cancer were less likely to undergo cytoreductive surgery and less likely to complete planned chemotherapy. Although survival was generally longer among patients receiving surgical treatment, performance status rather than chronological age emerged as the most consistent independent prognostic factor. These findings support an individualized treatment approach based on functional status, disease characteristics, and treatment feasibility rather than age alone.
Förderung
- Lunds Universitet
Zitieren
APA
Norbeck, A., Alson, S., Liuba, K., & Asp, M. (2026). Treatment patterns and outcomes in elderly patients with ovarian cancer: a real-world data analysis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1977324
Vancouver
Norbeck A, Alson S, Liuba K, Asp M. Treatment patterns and outcomes in elderly patients with ovarian cancer: a real-world data analysis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1977324
BibTeX
@article{Norbeck2026,
author = {Norbeck, Anna and Alson, Sara and Liuba, Karina and Asp, Mihaela},
title = {Treatment patterns and outcomes in elderly patients with ovarian cancer: a real-world data analysis},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1977324}
}
EUVIMED